71 related articles for article (PubMed ID: 8458020)
21. Changes in creatine phosphate, inorganic phosphate, and the purine pattern in dog hearts with time of coronary artery occlusion and effect thereon of mioflazine, a nucleoside transport inhibitor.
Van Belle H; Wynants J; Xhonneux R; Flameng W
Cardiovasc Res; 1986 Sep; 20(9):658-64. PubMed ID: 3791355
[TBL] [Abstract][Full Text] [Related]
22. The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs.
Wainwright CL; Parratt JR; Van Belle H
Br J Pharmacol; 1993 Jun; 109(2):592-9. PubMed ID: 8358559
[TBL] [Abstract][Full Text] [Related]
23. A new concept of long-term donor heart preservation: nucleoside transport inhibition.
Flameng W; Sukehiro S; Möllhoff T; Van Belle H; Janssen P
J Heart Lung Transplant; 1991; 10(6):990-8. PubMed ID: 1756166
[TBL] [Abstract][Full Text] [Related]
24. Effect of nucleoside transport inhibition on adenosine and hypoxanthine accumulation in the ischemic human myocardium.
Masuda M; Sukehiro S; Möllhoff T; Van Belle H; Flameng W
Arch Int Pharmacodyn Ther; 1993; 322():45-54. PubMed ID: 8215716
[TBL] [Abstract][Full Text] [Related]
25. The cardioprotective effects of R 75231 and lidoflazine are not caused by adenosine A1 receptor activation.
Grover GJ; Sleph PG
J Pharmacol Exp Ther; 1994 Jan; 268(1):90-6. PubMed ID: 8301599
[TBL] [Abstract][Full Text] [Related]
26. Nucleoside transporter expression and function in cultured mouse astrocytes.
Peng L; Huang R; Yu AC; Fung KY; Rathbone MP; Hertz L
Glia; 2005 Oct; 52(1):25-35. PubMed ID: 15892125
[TBL] [Abstract][Full Text] [Related]
27. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine?
Van Belle H
Cardiovasc Res; 1993 Jan; 27(1):68-76. PubMed ID: 8458034
[No Abstract] [Full Text] [Related]
28. Cardioprotective effects of adenosine transport inhibition during reversible ischaemia in patients with coronary artery disease.
Ottervanger JP; Gregor P; Widimsky P; Zijlstra F; Kluiver EP; Hof AW; Suryapranata H
Int J Cardiovasc Intervent; 1999; 2(3):181-186. PubMed ID: 12623587
[TBL] [Abstract][Full Text] [Related]
29. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH.
Barnes K; Dobrzynski H; Foppolo S; Beal PR; Ismat F; Scullion ER; Sun L; Tellez J; Ritzel MW; Claycomb WC; Cass CE; Young JD; Billeter-Clark R; Boyett MR; Baldwin SA
Circ Res; 2006 Sep; 99(5):510-9. PubMed ID: 16873718
[TBL] [Abstract][Full Text] [Related]
30. Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells.
Parkinson FE; Geiger JD
J Pharmacol Exp Ther; 1996 Jun; 277(3):1397-401. PubMed ID: 8667202
[TBL] [Abstract][Full Text] [Related]
31. Role of nucleoside transport and purine release in a rabbit model of myocardial stunning.
Abd-Elfattah AS; Maddox RP; Jessen ME; Rebeyka IM; Wechsler AS
Mol Cell Biochem; 1998 Mar; 180(1-2):145-51. PubMed ID: 9546641
[TBL] [Abstract][Full Text] [Related]
32. Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep.
SenGupta DJ; Unadkat JD
Biochem Pharmacol; 2004 Feb; 67(3):453-8. PubMed ID: 15037197
[TBL] [Abstract][Full Text] [Related]
33. Adenosine plays a role in food-induced jejunal hyperemia.
Sawmiller DR; Chou CC
Am J Physiol; 1988 Aug; 255(2 Pt 1):G168-74. PubMed ID: 3407776
[TBL] [Abstract][Full Text] [Related]
34. The differential cardioprotective effects of nucleoside transport inhibitor on moderate and deep hypothermic ischemia with cold cardioplegia.
Nishida T; Masuda M; Kanegae Y; Miyamoto K; Tominaga R; Kawachi Y; Yasui H
Surg Today; 2000; 30(9):805-10. PubMed ID: 11039708
[TBL] [Abstract][Full Text] [Related]
35. Endogenous catecholamines during noradrenaline and adrenaline hypertension.
Garbuliński T; Switała M
Pol J Pharmacol Pharm; 1979; 31(2):89-96. PubMed ID: 493182
[TBL] [Abstract][Full Text] [Related]
36. Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice leads to altered nucleoside levels following hypoxic challenge.
Rose JB; Naydenova Z; Bang A; Ramadan A; Klawitter J; Schram K; Sweeney G; Grenz A; Eltzschig H; Hammond J; Choi DS; Coe IR
Life Sci; 2011 Oct; 89(17-18):621-30. PubMed ID: 21872611
[TBL] [Abstract][Full Text] [Related]
37. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium: relevance to therapeutic preconditioning in humans.
Gamboa A; Ertl AC; Costa F; Farley G; Manier ML; Hachey DL; Diedrich A; Biaggioni I
Circulation; 2003 Nov; 108(21):2631-5. PubMed ID: 14623808
[TBL] [Abstract][Full Text] [Related]
38. Effects of nucleoside transport inhibitors and adenine/ribose supply on ATP concentration and adenosine production in cardiac myocytes.
Kalsi KK; Smolenski RT; Yacoub MH
Mol Cell Biochem; 1998 Mar; 180(1-2):193-9. PubMed ID: 9546646
[TBL] [Abstract][Full Text] [Related]
39. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart.
Tsuchida A; Thompson R; Olsson RA; Downey JM
J Mol Cell Cardiol; 1994 Mar; 26(3):303-11. PubMed ID: 8028014
[TBL] [Abstract][Full Text] [Related]
40. Plasticity of cardiovascular nucleoside transporters following chronic dipyridamole treatment.
Williams EF
SAAS Bull Biochem Biotechnol; 1997; 10():19-24. PubMed ID: 9274058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
